Clinical Trial Detail

NCT ID NCT03071406
Title Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors H. Lee Moffitt Cancer Center and Research Institute

Merkel cell carcinoma


Ipilimumab + Nivolumab

Age Groups: adult senior

No variant requirements are available.